Camrelizumab Combined With Chemotherapy and Local Treatment in Non-small Cell Lung Cancer Patients With Brain Metastasis, a Single-arm, Multi-center, Open-labeled Phase II Clinical Trial
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Camrelizumab (Primary) ; Pemetrexed
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Oct 2023 Results (Between May 6, 2020 and April 25, 2023 (data cutoff), n=65) assessing preliminary efficacy and safety of brain RT combined with camrelizumab plus platinum-based chemotherapy as first-line treatment in NSCLC patients presented at the 48th European Society for Medical Oncology Congress
- 03 Sep 2021 Planned number of patients changed from 20 to 63.
- 03 Sep 2021 Planned End Date changed from 1 Jan 2023 to 30 Jun 2023.